Role of Neurotrophin-4/5 in Neural Cell Death during Retinal Development and Ischemic Retinal Injury In Vivo

Chikako Harada, Takayuki Harada, Hun-Meng A. Quah, Kazubiko Namekata, Kazubiko Yoshida, Shigeaki Obno, Kobichi Tanaka, and Luis F. Parada

PURPOSE. Neurotrophin (NT)-4/5 and brain-derived neurotrophic factor (BDNF) mediate cell survival through TrkB, a high-affinity tyrosine kinase receptor, and may prevent neural cell death in various pathologic conditions. This study was conducted to investigate the function of NT-4/5 in neural cell death during retinal development and ischemic retinal injury.

METHODS. Retinal development in wild-type, NT-4/5 knockout (KO), and NT-4/5:BDNF double-KO mice was histologically examined from postnatal day 0 (P0) to P90. Ischemic retinal injury was performed at P42, and NT-4/5 mRNA expression level and the extent of retinal cell death was quantitatively examined.

RESULTS. Real-time PCR analysis revealed increased NT-4/5 mRNA expression in the ischemic retina. In the NT-4/5 KO mouse, retinal development and structure were normal, but the strain was susceptible to ischemic injury on P42. In contrast, NT-4/5:BDNF double-KO mice showed delayed retinal development and died before P42.

CONCLUSIONS. These results suggest that NT-4/5, in combination with other trophic factors, is involved in the postnatal survival of retinal neurons during both development and degeneration.

From the 1Department of Molecular Neurobiology, Tokyo Metropolitan Institute for Neuroscience, Fuchu, Tokyo, Japan; the 2Laboratory of Molecular Neurobiology, School of Biomedical Science and Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan; the 3Center for Developmental Biology and the 4Kent Waldrep Foundation Center for Basic Research on Nerve Growth and Regeneration, University of Texas Southwestern Medical Center, Dallas, Texas; the 5Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan; and the 6PRESTO, Japan Science and Technology Corporation, Kawaguchi, Saitama, Japan.

Supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan. CH was supported by the Uchera Memorial Foundation postdoctoral fellowship and the Japan Society for the Promotion of Science for Young Scientists. TH was supported by a Human Frontier Science Program long-term fellowship (LT00170/2001-B). LFP is supported by the National Institute for Neurological Disorders and Stroke (NINDS) and the Christopher Reeve Paralysis Foundation.

Submitted for publication July 14, 2004; revised September 17, 2004; accepted November 6, 2004.

Disclosure: C. Harada, None; T. Harada, None; H.-M.A. Quah, None; K. Namekata, None; K. Yoshida, None; S. Ohno, None; K. Tanaka, None; L.F. Parada, None.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Takayuki Harada, Department of Molecular Neurobiology, Tokyo Metropolitan Institute for Neuroscience, 24 Musashidai, Fuchu, Tokyo 183-8526, Japan; harada@tmn.ac.jp.

Copyright © Association for Research in Vision and Ophthalmology

The growth factors in the neurotrophin family, which include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin (NT-4/5), play important roles in the development of retina and visual system. 1–6 For example, limiting amounts of neurotrophins in the target area of the superior colliculus may control the apoptosis of retinal ganglion cells (RGCs) during the early postnatal period. In support of this hypothesis, NT-4/5 or BDNF injected into the superior colliculus promotes the survival of neonatal RGCs. 7,8 Control of cell survival by neurotrophins is mediated by two types of transmembrane glycoproteins: the trkB tyrosine kinase receptors (TrkA, TrkB, and TrkC) and the neurotrophin receptor p75 (p75NTR). 1,9,10 Neurotrophins act in neural cell survival by activating trkB tyrosine kinases, downstream of which a ras-dependent pathway leads to the activation of mitogen-activated protein (MAP) kinases. 9,10

Neurotrophins are also involved in the survival of adult retinal neurons. For example, intraocular injection of NGF, BDNF, and NT-4/5 rescues RGCs after axotomy. 11–17 In addition, we recently found that neurotrophic factors released from retinal glia are involved in the process of photoreceptor degeneration. 18–20

Another important pathologic condition that kills retinal neurons is ischemic injury. Ischemic injury is mainly associated with excessive concentrations of glutamate, which results in overactivation of glutamate receptors and initiates a cascade of events that leads to necrosis and/or apoptosis. Consistently, retinal neurons can be protected by glutamate receptor antagonists 21,22 and by selective inhibition of N-acetylated-a-linked acidic dipeptidase (NAAADase), which is an enzyme responsible for the hydrolysis of neuropeptide N-acetyl-aspartyl-glutamate to N-acetyl-aspartate and glutamate. 23 We also have demonstrated that glutamate transporters are crucial for the protection of retinal cells from ischemic injury. 24 A recent study in mice lacking both alleles for NT-4/5 or deficient in a single allele for BDNF has shown that expression of both NT-4/5 and BDNF, the high-affinity TrkB ligands, confers resistance to ischemic brain injury. 25 However, such a study has not yet been performed in the retina. In the present study, we examined the role of NT-4/5 and BDNF during retinal development and degeneration after ischemic injury in vivo.

MATERIALS AND METHODS

Animals

Experiments were performed in NT-4/5 KO 26 and NT-4/5:BDNF double-KO (NT-4/5:BDNF DKO) 27 mice, in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. For developmental studies, five NT-4/5 KO mice were killed on each of postnatal day (P0), P5, P17, and P42 and five NT-4/5:BDNF DKO mice were killed on each of P0, P5, P17. Ischemic injury was performed at P42.
Ischemic Retinal Injury

Ischemia was achieved, and the animals were treated essentially as previously described. \(^{23,24,28}\) Briefly, we instilled sterile saline into the anterior chamber of the left eye at 120 cm H\(_2\)O pressure for 20 or 40 minutes, whereas the right eye served as the nons ischemic control. Seven days after reperfusion, animals were anesthetized with diethyl ether and perfused transcardially with saline, followed by 4% paraformaldehyde in 0.1 M phosphate buffer containing 0.5% picric acid at room temperature. The eyes were removed and postfixed overnight in the same fixative at 4°C and embedded in paraffin wax. The posterior part of the eyes was sectioned sagittally at 7 μm thickness through the optic nerve, mounted, and stained with hematoxylin and eosin. Ischemic damage was quantified in two ways. \(^{25}\) First, the thickness of the inner retinal layer (IRL), between the internal limiting membrane and the interface of the outer plexiform layer (OPL) and the outer nuclear layer (ONL), was measured. Second, in the same sections, the number of neurons in the ganglion cell layer (GCL) was counted from one ora serrata through the optic nerve to the other ora serrata. The changes of the number of cells after ischemia were expressed in ratio compared with the nonischemic fellow eyes. Total RNA for PCR was prepared from whole retina 6 hours, 12 hours, 1 day, 3 days, and 7 days after ischemic injury. \(^{28,29}\)

Quantitative Real-Time PCR Analysis

After RNA isolation and cDNA synthesis, the quality of the cDNA was controlled by PCR, using mouse-specific primers for glyceraldehyde-3-phosphate dehydrogenase (G3PDH); sense: 5'-ACC ACA GTC CAT GCC ATC ACC-3'; antisense: 5'-TCC ACC ACC CTG TTG CTG TA-3'. Amplification of the expected PCR product (452 bp) was successful in all samples (data not shown).

Real-time RT-PCR (TaqMan PCR on the PRISM 7700 Sequence Detection System; Applied Biosystems, Inc. [ABI], Foster City, CA) was performed according to the manufacturer’s protocol. The internal probe was labeled with the reporter dye FAM (6-carboxylfluorescein) at the 5' end and with the quencher dye TAMRA (6-carboxytetramethylrhodamine) at the 3' end. For NT-4/5, two primers (forward primer, 5'-GAGGCACCTGGCCTCGAAGATG-3'; reverse primer, 5'-GGAATCCAGCGCCGACG-3') and one probe (5'-FAM-CAGTCTCTAGTGCGGGGC-VIC-3') were used. For G3PDH, two primers (forward primer, 5'-TGACACCAACAACTGGTCTAG-3'; reverse primer, 5'-GGATGCAGGGATGATGGTC-3') and one probe (5'-VIC-CAGAAGACTGTTGCGG-3') were used.

cDNA (50 ng) was reacted in a total volume of 20 μL with a master mix (TaqMan Universal PCR Master Mix; ABI). The final concentrations of probe and other primers were 200 and 400 nM, respectively. The conditions for PCR were as follows: 95°C for 15 seconds and 60°C for 1 minute. The difference in the initial amount of total RNA between the samples was normalized in every assay by using the G3PDH gene expression as an internal standard. In each cDNA, the ratio of the copy number of NT-4/5 mRNA was divided by that of the G3PDH mRNA. This normalized value was used to determine the relative expression level of NT-4/5.

Immunoblot

Membrane extracts were prepared by homogenizing whole retina 24 hours after ischemic injury, in 8 to 10 volumes of ice-cold 50 mM Tris-HCl (pH 7.5) containing 150 mM NaCl. Three micrograms of the protein samples were electrophoresed on a 5% to 20% sodium dodecyl sulfate-polyacrylamide gradient gel and subsequently transferred to a polyvinylidene difluoride filter (Immobilon-P; Millipore, Billerica, MA). The membrane was incubated with an anti-NT-4/5, affinity-purified polyclonal antibody (1 mg/mL; Santa Cruz Biotechnology, Santa Cruz, CA), or β-tubulin (1 mg/mL; Sigma-Aldrich, St. Louis, MO), and visualized with a chemiluminescence Western blot kit (Roche Diagnostics, Mannheim, Germany).

RESULTS

NT-4/5 Expression in the Ischemic Retina

Ischemic stress induces neural cell loss, mainly in the inner part of the retina. \(^{23,24,28}\) To examine NT-4/5 mRNA expression levels in the ischemic retina, we performed quantitative real-time PCR analysis. As shown in Figure 1A, NT-4/5 mRNA expression increased significantly at 12 hours and 1 day after ischemic injury (\(P < 0.05\)) and returned to its normal level after 3 days. Consistently, compared with the internal standard (β-tubulin), NT-4/5 protein expression was upregulated 1 day after ischemic injury (Fig. 1B). These results suggest the pos-

FIGURE 1. NT-4/5 expression after ischemic retinal injury. (A) Quantitative analysis of NT-4/5 mRNA expression was performed 6 hours, 12 hours, 1 day, 3 days, and 7 days after ischemic retinal injury. Each data point represents the mean ± SEM of the values obtained from six independent experiments. *\(P < 0.05\). (B) NT-4/5 protein expression was examined 1 day after ischemic injury by Western blot. Representative data of three independent experiments are presented.
function of NT-4/5 in the retina

we next examined the effect of ischemic injury in WT and NT-4/5 KO mice. Histologic evaluation demonstrated a significant increase in ischemic damage in the NT-4/5 KO mice (Fig. 3C) compared with their WT littermates (Fig. 3B). The thickness of the IRL after 20 minutes of ischemia was 80% ± 7% (n = 6) in WT, but only 65% ± 8% (n = 6) in NT-4/5 KO mice (P < 0.05; Fig. 4A). Second, the percentage of surviving cells in the GCL was also decreased in NT-4/5 KO mice (54% ± 10%; n = 6; P < 0.05) compared with their WT littermates (74% ± 9%; n = 6; Fig. 4B). Similar results were observed after 40 minutes of ischemic injury (Figs. 4A, 4B). We also quantified retinal cell apoptosis 1 and 3 days after 20 minute ischemia. An ELISA demonstrated increased retinal cell apoptosis in NT-4/5 KO mice (125% ± 10% after 1 day and 121% ± 6% after 3 days) compared with WT littermates (100% ± 3% after 1 day and 100% ± 4% after 3 days; Fig. 4C). Thus, loss of endogenous NT-4/5 has a detrimental effect on inner retinal neurons during ischemic injury.

retinal development in NT-4/5:BDNF DKO mice

because NT-4/5 and BDNF mediate cell survival through the same high-affinity tyrosine kinase receptor, TrkB, we further tried to examine the ischemic damage in NT-4/5:BDNF DKO mice. However, we could not perform the experiments because most of the mice died within the first postnatal week.27 In NT-4/5:BDNF DKO retina, OPL formation was not clear at P5 (Fig. 2J, arrow) and the GCL was still composed of multiple layers at P17 (Fig. 2K, asterisk). Although we could not examine NT-4/5:BDNF DKO retina beyond P18, the absence of both NT-4/5 and BDNF led to delayed development in the inner retina.

discussion

in the present study, NT-4/5 afforded neuronal cell protection against ischemic retinal injury in vivo. Ischemic retinal injury is now implicated in a number of pathologic states, such as retinal artery occlusion, glaucoma, and diabetic retinopathy.21-24,28 although long-term effects of NT-4/5 is limited in axotomized RGCs,30 our present results suggest the possibility of management of ischemic injury with NT-4/5. Because other trophic factors, such as ciliary neurotrophic factor (CNTF) and glial cell line-derived neurotrophic factor (GDNF), also increase RGC survival and regeneration,15,14,16,17,51,52 treatment by NT-4/5 in combination with these trophic factors may stimulate multiple cellular targets and activate separate mechanisms to prevent ischemia-induced neuronal cell death.

in addition, endogenous NT-4/5, in combination with BDNF, was required for normal retinal development. Retinal development is normal in NT-4/5 KO (Fig. 2E-H) and BDNF KO mice (data not shown). This may have occurred be-
cause of compensation by other trophic factors such as NT-3, because NT-3 is another possible ligand for TrkB, and its expression level is relatively high in the retina. 55–57 In contrast, NT-4/5:BDNF DKO mice showed unexpected delay in inner retinal development, and the GCL was still composed of multiple layers (Figs. 2I–K). The absence of NT-4/5 or BDNF compensated for each other, possibly with NT-3, but NT-3 alone may not be enough to compensate for the lack of two major TrkB ligands. In any event, these results suggest that NT-4/5 is involved in the postnatal survival of retinal neurons during both development and degeneration.

Our present findings may be of clinical relevance if NT-4/5 and its related molecules are to be used therapeutically in the treatment of human retinal diseases that otherwise lead to severe visual impairment. Recent studies have shown that neurotrophins may stimulate the glia–neuron pathway that indirectly leads to neural cell survival. 16–20,58 Because neurotrophin receptors are upregulated in Müller glial cells during retinal degeneration, 16–20,59–61 Müller cells may be another target for neuroprotection. In contrast, the mammalian TrkB locus undergoes alternative splicing to produce full-length and truncated receptors lacking the intracellular tyrosine kinase domain. Of note, truncated TrkB receptors may negatively influence neuron survival by interfering with the function of catalytic TrkB receptors. 62 Thus, overexpression of full-length TrkB or selective inhibition of truncated TrkB receptors may be effective during retinal degeneration. To find a better therapeutic method, further investigations on the precise role of NT-4/5 and its related molecules in other forms of retinal degeneration are necessary.

References


